Goldman Sachs Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $47

Benzinga · 05/08 15:01
Goldman Sachs analyst Salveen Richter maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $53 to $47.